Innate Pharma Gets $50 Million Milestone Payment From AstraZeneca
23 Oktober 2020 - 2:00PM
Dow Jones News
By Chris Wack
Innate Pharma SA said Friday that AstraZeneca has dosed the
first patient in its Phase 3 clinical trial evaluating monalizumab
in combination with cetuximab in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck.
Dosing of the first patient in the trial has triggered a $50
million milestone payment from AstraZeneca to Innate.
Innate said the milestone payment fortifies its cash position
through the end of 2022.
The company said the combination of monalizumab and cetuximab
demonstrated a manageable safety profile and a response rate of
27.5%.
Innate Pharma shares were up 12%, to $4.41, in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 23, 2020 07:45 ET (11:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
